Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells

Ribeiro, Andreia; Laranjeira, Paula; Mendes, Sandrine; Velada, Isabel; Leite, Cristiana; Andrade, Pedro; Santos, Francisco; Henriques, Ana; Grãos, Mário; Cardoso, Carla M P; Martinho, António; Pais, M Luísa; da Silva, Cláudia Lobato; Cabral, Joaquim; Trindade, Hélder; Paiva, Artur

doi:10.1186/scrt336

Stem Cell Research & Therapy

Table 2 Distribution of T, B and NK cells among the respective activation compartments

From: Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells

		MNC	MNC + BM-MSCs	MNC + UCM-MSCs	MNC + AT-MSCs	MNC + PHA	MNC + PHA + BM-MSCs	MNC + PHA + UCM-MSCs	MNC + PHA + AT-MSCs
Cell type	Subpopulation	n = 17	n = 5	n = 7	n = 5	n = 17	n = 5	n = 7	n = 5
Total T cells		82 ± 5	80 ± 11	80 ± 7	86 ± 5	86 ± 3	79 ± 8	71 ± 17	86 ± 5
CD4 ⁺ T cells		81 ± 5	81 ± 9	77 ± 9	84 ± 3	77 ± 3	84 ± 7	67 ± 8	76 ± 10
	CD69^-CD25^-HLA-DR^-	100 ± 0	100 ± 0	99 ± 2	100 ± 0	25 ± 7	23 ± 8	18 ± 9	43 ± 17^{a; b; c; d}
	CD69⁺CD25^-HLA-DR^-	0 ± 0	0 ± 0	1 ± 2	0 ± 0	6 ± 1	14 ± 4^{a; d}	15 ± 8^{a; d}	13 ± 1^{a; d}
	CD69⁺CD25⁺HLA-DR^-	0 ± 0	0 ± 0	0 ± 0	0 ± 0	67 ± 7	58 ± 6^a	66 ± 17	43 ± 18^{a; d}
	CD69⁺CD25⁺HLA-DR⁺	0 ± 0	0 ± 0	0 ± 0	0 ± 0	3 ± 2	4 ± 2	2 ± 2	1 ± 0
CD8 ⁺ T cells		19 ± 5	19 ± 9	23 ± 9	14 ± 3	23 ± 3	16 ± 7	33 ± 8	24 ± 10
	CD69^-CD25^-HLA-DR^-	99 ± 0	99 ± 2	98 ± 3	100 ± 1	18 ± 10	22 ± 3	12 ± 1^b	41 ± 12^{a; b; c; d}
	CD69⁺CD25^-HLA-DR^-	1 ± 0	1 ± 2	2 ± 2	0 ± 1	9 ± 1	16 ± 4^{a; d}	18 ± 9^{a; d}	14 ± 2^a
	CD69⁺CD25⁺HLA-DR^-	0 ± 0	0 ± 0	0 ± 0	0 ± 0	68 ± 11	59 ± 6^a	67 ± 10	45 ± 14^{a; b; c; d}
	CD69⁺CD25⁺HLA-DR⁺	0 ± 0	0 ± 0	0 ± 0	0 ± 0	4 ± 2	2 ± 3^d	2 ± 2	1 ± 1
B cell		2 ± 0	2 ± 1	4 ± 4	3 ± 2	3 ± 1	4 ± 1	4 ± 3	3 ± 2
	CD69^-CD25^-	98 ± 1	95 ± 4	97 ± 3	98 ± 1	40 ± 6	63 ± 23	37 ± 9	72 ± 15^{a; d}
	CD69⁺CD25^-	2 ± 1	5 ± 4	3 ± 3	2 ± 1	56 ± 7	32 ± 15^d	60 ± 6^b	27 ± 14^{a; d}
	CD69⁺CD25⁺	0 ± 0	0 ± 0	0 ± 0	0 ± 0	4 ± 3	5 ± 10	4 ± 4	1 ± 1
Total NK cells		16 ± 5	19 ± 10	16 ± 5	12 ± 5	12 ± 2	20 ± 9	20 ± 9	11 ± 5
CD56 ^bright NK cells		3 ± 1	2 ± 1	3 ± 2	4 ± 3	8 ± 0	6 ± 3	6 ± 5	8 ± 4
	CD69^-CD25^-	99 ± 0	99 ± 1	99 ± 3	100 ± 1	82 ± 2	94 ± 2^{a; d}	80 ± 20	97 ± 1^{a; b; d}
	CD69⁺CD25^-	1 ± 0	1 ± 1	1 ± 3	0 ± 1	17 ± 2	6 ± 2^{a; d}	18 ± 17	3 ± 1^{a; b; d}
	CD69⁺CD25⁺	0 ± 0	0 ± 0	0 ± 0	0 ± 0	1 ± 0	1 ± 0	2 ± 3	1 ± 0
CD56 ^dim NK cells		97 ± 1	98 ± 1	97 ± 2	96 ± 3	92 ± 0	94 ± 3	94 ± 3	92 ± 4
	CD69^-CD25^-	97 ± 2	96 ± 7	97 ± 4	99 ± 1	29 ± 3	73 ± 18^{a; d}	74 ± 6^{a; d}	79 ± 19^{a; d}
	CD69⁺CD25^-	3 ± 2	4 ± 7	3 ± 4	1 ± 1	68 ± 2	25 ± 17^{a; d}	25 ± 6^{a; d}	20 ± 19^{a; d}
	CD69⁺CD25⁺	0 ± 0	0 ± 0	0 ± 0	0 ± 0	3 ± 0	1 ± 1	1 ± 1	1 ± 0

Distribution (mean ± standard deviation) of total T cells, CD4⁺ and CD8⁺ T cells, B cells, total NK cells and CD56^dim and CD56^bright NK cells in the MNC culture and among the following activation stages: non-activated CD69^-CD25^-HLA-DR^-, earlier activated CD69⁺CD25^-HLA-DR^-, intermediate activated CD69⁺CD25⁺HLA-DR^-, and later activated CD69⁺CD25⁺HLA-DR⁺, for T cell subpopulations; and non-activated CD69^-CD25^-, earlier activated CD69⁺CD25^- and activated CD69⁺CD25⁺, for B cells and NK cell subpopulations. MNC were subjected to different culture conditions: absence or presence of PHA and absence or presence of MSCs from different sources.
Results are expressed as mean percentage ± standard deviation. Statistically significant differences were considered when P <0,05 for Mann–Whitney test:^acomparing with MNC + PHA; ^bcomparing with MNC + PHA + BM-MSCs; ^ccomparing with MNC + PHA + UCM-MSCs. Statistically significant differences were considered when P <0,05 for Wilcoxon paired-sample test: ^dcomparing with MNC + PHA.
AT, adipose tissue; BM, bone marrow; MNC, mononuclear cells; MSCs, mesenchymal stem cells; PHA, phytohemagglutinin; UCM, umbilical cord matrix.

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com